Literature DB >> 32354389

Circulating Ceramide 16:0 in Heart Failure With Preserved Ejection Fraction.

Ali Javaheri, Jeremy C Allegood, L Ashley Cowart, Julio A Chirinos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32354389      PMCID： PMC7375158          DOI： 10.1016/j.jacc.2020.02.062

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  5 in total

Review 1.  Could Ceramides Become the New Cholesterol?

Authors:  Scott A Summers
Journal:  Cell Metab       Date:  2018-01-04       Impact factor: 27.287

2.  Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk.

Authors:  Rozenn N Lemaitre; Paul N Jensen; Andrew Hoofnagle; Barbara McKnight; Amanda M Fretts; Irena B King; David S Siscovick; Bruce M Psaty; Susan R Heckbert; Dariush Mozaffarian; Nona Sotoodehnia
Journal:  Circ Heart Fail       Date:  2019-07-12       Impact factor: 8.790

3.  Ceramide Synthase 5 Is Essential to Maintain C16:0-Ceramide Pools and Contributes to the Development of Diet-induced Obesity.

Authors:  Dominic Gosejacob; Philipp S Jäger; Katharina Vom Dorp; Martin Frejno; Anne C Carstensen; Monika Köhnke; Joachim Degen; Peter Dörmann; Michael Hoch
Journal:  J Biol Chem       Date:  2016-02-07       Impact factor: 5.157

4.  Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.

Authors:  Reijo Laaksonen; Kim Ekroos; Marko Sysi-Aho; Mika Hilvo; Terhi Vihervaara; Dimple Kauhanen; Matti Suoniemi; Reini Hurme; Winfried März; Hubert Scharnagl; Tatjana Stojakovic; Efthymia Vlachopoulou; Marja-Liisa Lokki; Markku S Nieminen; Roland Klingenberg; Christian M Matter; Thorsten Hornemann; Peter Jüni; Nicolas Rodondi; Lorenz Räber; Stephan Windecker; Baris Gencer; Eva Ringdal Pedersen; Grethe S Tell; Ottar Nygård; Francois Mach; Juha Sinisalo; Thomas F Lüscher
Journal:  Eur Heart J       Date:  2016-04-28       Impact factor: 29.983

5.  Ceramide Remodeling and Risk of Cardiovascular Events and Mortality.

Authors:  Linda R Peterson; Vanessa Xanthakis; Meredith S Duncan; Stefan Gross; Nele Friedrich; Henry Völzke; Stephan B Felix; Hui Jiang; Rohini Sidhu; Matthias Nauck; Xuntian Jiang; Daniel S Ory; Marcus Dörr; Ramachandran S Vasan; Jean E Schaffer
Journal:  J Am Heart Assoc       Date:  2018-05-03       Impact factor: 5.501
  5 in total
  6 in total

1.  Bioactive lipids and metabolic syndrome-a symposium report.

Authors:  Loren M DeVito; Edward A Dennis; Barbara B Kahn; Gerald I Shulman; Joseph L Witztum; Sudeshna Sadhu; Joseph Nickels; Matthew Spite; Susan Smyth; Sarah Spiegel
Journal:  Ann N Y Acad Sci       Date:  2022-02-25       Impact factor: 6.499

Review 2.  Ceramides and other sphingolipids as drivers of cardiovascular disease.

Authors:  Ran Hee Choi; Sean M Tatum; J David Symons; Scott A Summers; William L Holland
Journal:  Nat Rev Cardiol       Date:  2021-03-26       Impact factor: 49.421

Review 3.  Sphingolipids in the Heart: From Cradle to Grave.

Authors:  Anna Kovilakath; Maryam Jamil; Lauren Ashley Cowart
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-15       Impact factor: 5.555

Review 4.  Role of Ceramides in the Molecular Pathogenesis and Potential Therapeutic Strategies of Cardiometabolic Diseases: What we Know so Far.

Authors:  Youssef M Shalaby; Anas Al Aidaros; Anjana Valappil; Bassam R Ali; Nadia Akawi
Journal:  Front Cell Dev Biol       Date:  2022-01-19

Review 5.  Sphingolipid metabolism and signaling in cardiovascular diseases.

Authors:  Sonia Borodzicz-Jażdżyk; Piotr Jażdżyk; Wojciech Łysik; Agnieszka Cudnoch-Jȩdrzejewska; Katarzyna Czarzasta
Journal:  Front Cardiovasc Med       Date:  2022-08-31

Review 6.  Sphingolipids in metabolic disease: The good, the bad, and the unknown.

Authors:  Christopher D Green; Michael Maceyka; L Ashley Cowart; Sarah Spiegel
Journal:  Cell Metab       Date:  2021-07-06       Impact factor: 31.373
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.